within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AD65_MacrogolCombinations;

model MacrogolCombinations
  extends Pharmacolibrary.Drugs.ATC.A.A06AD65
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.01,
    Cl             = 1.3888888888888888e-07,
    adminDuration  = 600,
    adminMass      = 17000 / 1000000,
    adminCount     = 1,
    Vd             = 0.009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600  
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>MacrogolCombinations</td></tr><tr><td>ATC code:</td><td>A06AD65</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>17000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Macrogol (also known as polyethylene glycol) combinations are used primarily as osmotic laxatives to treat constipation and to facilitate bowel cleansing before diagnostic procedures such as colonoscopy. Macrogol is widely used and approved for these indications in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for macrogol combinations in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Hruska, MW, et al., &amp; Marsteller, DA (2024). Population Pharmacokinetics of Naloxegol in Pediatric Subjects Receiving Opioids. <i>Clinical pharmacology in drug development</i> 13(9) 974–984. DOI:<a href=\"https://doi.org/10.1002/cpdd.1457\">10.1002/cpdd.1457</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39110083/\">https://pubmed.ncbi.nlm.nih.gov/39110083</a></p></li><li><p>Keating, GM, &amp; Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. <i>Drugs</i> 63(7) 701–730. DOI:<a href=\"https://doi.org/10.2165/00003495-200363070-00008\">10.2165/00003495-200363070-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12656650/\">https://pubmed.ncbi.nlm.nih.gov/12656650</a></p></li><li><p>Xu, C, et al., &amp; Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. <i>European journal of clinical pharmacology</i> 69(12) 2045–2054. DOI:<a href=\"https://doi.org/10.1007/s00228-013-1574-9\">10.1007/s00228-013-1574-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23975236/\">https://pubmed.ncbi.nlm.nih.gov/23975236</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end MacrogolCombinations;
